Analyzing Oncorus (NASDAQ:ONCR) & Perrigo (NYSE:PRGO)
Analyzing Oncorus (NASDAQ:ONCR) & Perrigo (NYSE:PRGO)
Oncorus (NASDAQ:ONCR – Get Rating) and Perrigo (NYSE:PRGO – Get Rating) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.
安可乐斯(纳斯达克代码：ONCR-GET Rating)和百利高(NYSE：PRGO-GET Rating)都是医疗公司，但哪只股票更好？我们将根据这两家公司的盈利能力、估值、收益、分析师建议、风险、机构所有权和股息等方面的实力进行对比。
Institutional and Insider Ownership
机构和内部人持股
65.9% of Oncorus shares are owned by institutional investors. Comparatively, 96.4% of Perrigo shares are owned by institutional investors. 15.9% of Oncorus shares are owned by company insiders. Comparatively, 0.8% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Oncorus 65.9%的股份由机构投资者持有。相比之下，Perrigo 96.4%的股份由机构投资者持有。Oncorus 15.9%的股份由公司内部人士持有。相比之下，Perrigo公司0.8%的股份由公司内部人士持有。强大的机构持股表明，对冲基金、大型基金管理公司和捐赠基金相信，一家公司有望实现长期增长。
Earnings & Valuation
收益与估值
This table compares Oncorus and Perrigo's top-line revenue, earnings per share and valuation.
此表比较了Oncorus和Perrigo的营收、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oncorus | N/A | N/A | -$64.76 million | ($2.96) | -0.15 |
| Perrigo | $4.14 billion | 1.03 | -$68.90 million | ($0.63) | -50.49 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 安科鲁斯 | 不适用 | 不适用 | -6,476万美元 | ($2.96) | -0.15 |
| Perrigo | 41.4亿美元 | 1.03 | -6,890万元 | ($0.63) | -50.49 |
Volatility & Risk
波动性与风险
Oncorus has a beta of 2.24, indicating that its share price is 124% more volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.
Oncorus的贝塔系数为2.24，表明其股价的波动性比标准普尔500指数高124%。相比之下，Perrigo的贝塔系数为0.84，这表明其股价的波动性比标准普尔500指数低16%。
Analyst Ratings
分析师评级
This is a summary of current recommendations and price targets for Oncorus and Perrigo, as provided by MarketBeat.com.
这是MarketBeat.com提供的Oncorus和Perrigo的当前建议和目标价的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oncorus | 0 | 2 | 1 | 0 | 2.33 |
| Perrigo | 0 | 0 | 3 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 安科鲁斯 | 0 | 2 | 1 | 0 | 2.33 |
| Perrigo | 0 | 0 | 3 | 0 | 3.00 |
Oncorus currently has a consensus target price of $5.25, indicating a potential upside of 1,090.48%. Perrigo has a consensus target price of $47.33, indicating a potential upside of 48.80%. Given Oncorus' higher probable upside, research analysts clearly believe Oncorus is more favorable than Perrigo.
Oncorus目前的共识目标价为5.25美元，表明潜在上行空间为1,090.48%。Perrigo的一致目标价为47.33美元，表明潜在上行空间为48.80%。鉴于Oncorus更有可能上行，研究分析师显然认为Oncorus比Perrigo更有利。
Profitability
盈利能力
This table compares Oncorus and Perrigo's net margins, return on equity and return on assets.
下表比较了Oncorus和Perrigo的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Oncorus | N/A | -72.31% | -42.11% |
| Perrigo | -1.93% | 5.31% | 2.47% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 安科鲁斯 | 不适用 | -72.31% | -42.11% |
| Perrigo | -1.93% | 5.31% | 2.47% |
Summary
摘要
Perrigo beats Oncorus on 7 of the 13 factors compared between the two stocks.
Perrigo在两只股票比较的13个因素中有7个击败了Oncorus。
About Oncorus
关于Oncorus
(Get Rating)
(获取评级)
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Oncorus，Inc.是一家临床阶段的生物制药公司，专注于为癌症患者开发病毒免疫疗法。该公司的主要候选产品是ONCR-177，这是一种肿瘤内注射的病毒免疫疗法，基于其溶瘤的单纯疱疹病毒1型平台，该平台正处于治疗各种癌症的I期临床试验。它还在开发ONCR-GBM，这是一种临床前阶段的OHSV计划，用于通过肿瘤内注射治疗脑癌；以及基于柯萨奇病毒A21和塞尼卡谷病毒的合成病毒免疫疗法。该公司与MSD International GmbH签署了一项临床试验合作和供应协议，以评估ONCR-177与默克公司的癌症免疫疗法KEYTRUDA在实体肿瘤患者的第一阶段临床试验中的安全性和耐受性。Oncorus，Inc.成立于2015年，总部位于马萨诸塞州剑桥市。
About Perrigo
关于Perrigo
(Get Rating)
(获取评级)
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, primarily in Europe. The company also offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Perrigo Company plc提供非处方药(OTC)健康和健康解决方案，通过使消费者能够预防或治疗可以自我管理的疾病来提高个人幸福感。该公司通过两个细分市场运营，即美国消费者自助服务和国际消费者自助服务。在美国、墨西哥、加拿大和南美，消费者自我护理部门主要专注于商店品牌、各类自我护理产品的开发、制造、营销和销售，包括上呼吸道、止痛和助眠产品、消化健康、营养、维生素、矿物质和补充剂、健康生活方式、皮肤护理和个人卫生以及口腔自我护理。该细分市场提供Prevacid 24HR、Good Sense、Zephrex D、Scaraway、Placker、Rbra、Steripod、Firefly、REACH、Dr.Fresh和Burt‘s Bees等品牌的产品。国际消费者自理部门通过一个由药房、批发商、药品和杂货店零售商以及辅助药房组成的网络，在大约23个国家和地区(主要是欧洲)开发、制造、营销和分销消费者自理品牌。该公司还提供代工服务。Perrigo Company plc成立于1887年，总部设在爱尔兰都柏林。
Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.
接受Oncorus Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Oncorus和相关公司的最新新闻和分析师评级的每日简要摘要。